General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | -0.37 | -0.3 | 0.07 | 18.92% |
2024-03-27 | 2023-12 | -0.39 | -0.34 | 0.05 | 12.82% |
2023-11-14 | 2023-09 | -0.42 | -0.35 | 0.07 | 16.67% |
2023-08-14 | 2023-06 | -0.37 | -0.37 | N/A | N/A |
2023-05-15 | 2023-03 | -0.31 | -0.32 | -0.01 | -3.23% |
2023-03-28 | 2022-12 | -0.3 | -0.67 | -0.37 | -123.33% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-06-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-25 | Oppenheimer | Upgrade | Outperform | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-06-14 | ALI-JACKSON KAMIL | Director | 11.76K | Purchase |
2019-03-14 | BARER SOL J | Director | 0.00 | Conversion of Exercise of derivative security |
2022-12-01 | BEDU-ADDO FRANK | Chief Executive Officer | 690.87K | Conversion of Exercise of derivative security |
2021-06-15 | BLOOMQUIST DELYLE WADE | Former | 798.91K | Purchase |
2021-06-14 | FREITAG GREGORY GENE | Director | 46.15K | Purchase |
2021-06-14 | GLOVER STEVE C | Director | 63.79K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 1.73M | 8.72M | 5.61% |
2023-06-29 | Vanguard Group Inc | 1.63M | 8.17M | 5.26% |
2023-06-29 | Geode Capital Management, LLC | 577.39K | 2.90M | 1.87% |
2023-06-29 | State Street Corporation | 456.98K | 2.30M | 1.48% |
2023-06-29 | Two Sigma Advisers, LP | 411.40K | 2.07M | 1.33% |
2023-09-29 | Inspirion Wealth Advisors LLC | 330.87K | 1.67M | 1.07% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 845.68K | 4.25M | 2.74% |
2023-08-30 | iShares Russell 2000 ETF | 631.39K | 3.71M | 2.05% |
2023-06-29 | Vanguard Extended Market Index Fund | 398.49K | 2.00M | 1.29% |
2023-07-30 | Fidelity Small Cap Index Fund | 244.97K | 1.40M | 0.79% |
2023-08-30 | iShares Russell 2000 Growth ETF | 228.53K | 1.34M | 0.74% |
2023-05-30 | Fidelity Extended Market Index Fund | 146.48K | 1.40M | 0.47% |
Split | Date |
---|---|
1 : 20 | 2019-03-18 |
Let’s see +9 today
$PDSB will close at 9 today
$PDSB looks promising let’s get that volume
@pdsb crazy to me that this stock is around and 5$. It should be 35$! What’s going on in Brazil, they need to start doing vaccinations in arms ASAP.
$PDSB: PDSB_Biotech
Updates that could come any day:
**PDS0201 -Tuberculosis - literally no mention of this since early last year.
**PDS0202 - Universal flu vaccine - NIAID grant awarded back in July for accelerated development. No word since then but you'd think they'd have some type of pre-clinical data at this point (Univ. of Kentucky is collaborator)
**PDS0203 - covid second generation vaccine - various articles indicate human trials starting in May in Brazil - no updates from company on funding by gov. or confirmation of trial timeline. EOY Ready through accelerated program in Brazil.
PDS0101 - (triple combo) - preliminary efficacy and safety data on additional 5 patients in 1st cohort. Interim data in Q2/Q3 per presentation. Additionally, "Confirmation that PDS0101 enhances the therapeutic benefit of M7824 & NHS IL-12 may lead to
expanded evaluation in several cancers with PDS0102-0104
Wild card: Funding news/partnerships for anything within their pipeline - eyes on PDS0104
PDSB Feb 2021 Biz presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/PDSB_Corporate_Overview_-_Feb_2021_FINAL.pdf
PDSB Website:
https://www.pdsbiotech.com/
$PDSB what chu talkin bout whilis?!
$PDSB know what you hold
$PDSB should see rally to 5 today
$PDSB going to be a great day! News comming in!
Imma try and buy the dip today
$PDSB Were making vaccines for Brazil Corona Virus. Hold long for massive gains
$PDSB The consortium is in talks with specific government agencies in Brazil to extend the preclinical funding to cover the upcoming human clinical trials expected to begin in H1 2021.